|
Alliance Pharma PLC on Friday said it expects to report 2024 profit broadly in line with the year before, despite a decline in annual revenue. The Chippenham, Wiltshire-based distributor of consumer healthcare brands and prescription medicines said it expects to report revenue of £180.3 million for 2024, down 1.3% from £182.7 million a year prior. Revenue within its Kelo-Cote franchise grew 3.4% at constant exchange rates to £65.4 million from £63.2 million, in line with its mid-single digit revenue growth forecast. The group is targeting a transition to smaller, more regular orders in China, though it notes that this is taking ‘longer than we anticipated’. Nizoral revenue sank 28% during the year to £16.4 million from £21.7 million, due to the timing of distributor orders, while Amberen revenue fell 10% to £10.1 million from £11.2 million. Total see-through Consumer Healthcare revenue declined 4.3% at CER to £130.7 million from £136.4 million. On the other hand, Prescription revenue grew 6.9% to £49.6 million, Forceval revenue rose 18% to £7.9 million, and Hydromol revenue was up 13% on-year to £10.3 million. Alliance Pharma still anticipates underlying group profit for the year in line with the £31.5 million reported for 2023. Chief Executive Officer Nick Sedgwick said: ‘I am pleased that performance in 2024 is in-line with expectations. Whilst we have much to do as we work on our transformation plans, I am confident that our strong portfolio of clinically differentiated brands will deliver predictable organic revenue growth over the mid-long term.’ Shares in Alliance Pharma were flat at 61.20 pence each in London on late Friday morning. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
